Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2021.03.30
年度召募资金使用鉴证报告
2021.03.30
关于深圳市多普乐实业生长有限公司2020年度业绩允许完成情形说明的鉴证报告
2021.03.30
商誉减值测试报告
2021.03.30
2020年年度审计报告
2021.03.30
第五届董事会第七次聚会决议通告
2021.02.23
Z6尊龙2020年面向及格投资者果真刊行公司债券(疫情防控债)...
2021.01.12
关于转让Kymab股权的通告
2021.01.12
第五届董事会第六次聚会决议通告
2020.12.22
关于控股股东股份扫除质押的通告
2020.12.16
2020年第四次暂时股东大会决议通告
第一页
上一页
20
21
22
23
24
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】